Welcome to the e-CCO Library!

P0606: The efficacy of upadacitinib in Intestinal Behçet's Disease refractory to anti-TNF-α therapy in a retrospective study
Year: 2025
Source: ECCO'25
Authors: Lux7x7x7 J.(1);Fangx7x7x7 Y.(1);Dux7x7x7 J.(1);Chenx7x7x7 C.(1)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0607: Opportunistic infections in patients with inflammatory bowel disease under advanced drug therapy. Real-word experience of 8 years from a medium-volume center in Cordobax7x7x7 Argentina.
Year: 2025
Source: ECCO'25
Authors: Torellox7x7x7 R.(1);Salvatierrax7x7x7 M.(1);Balderramox7x7x7 D.C.(2)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0608: Safety of guselkumab in Inflammatory Bowel Disease up to 1 year: Integrated safety analysis of phase 2 and 3 studies in Crohn’s Disease and Ulcerative Colitis
Year: 2025
Source: ECCO'25
Authors: Sandsx7x7x7 B.E.(1)*;Panaccionex7x7x7 R.(2);Danesex7x7x7 S.(3);Panésx7x7x7 J.(4);Hisamatsux7x7x7 T.(5);D’Haensx7x7x7 G.(6);Van Rampelberghx7x7x7 R.(7);Olurindex7x7x7 M.(8);Yeex7x7x7 J.(8);Bakerx7x7x7 T.(8);Yarandix7x7x7 S.(8);Germinarox7x7x7 M.(8);Vetterx7x7x7 M.L.(8);Lix7x7x7 H.(8);Rosas Ballinax7x7x7 M.(9);Allegrettix7x7x7 J.(10);Afzalix7x7x7 A.(11);Rubinx7x7x7 D.T.(12);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0609: Real-world short and long-term effectiveness of risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA Registry
Year: 2025
Source: ECCO'25
Authors: Barreiro-de Acostax7x7x7 M.(1)*;Nieto-Garciax7x7x7 L.(1);Poncelax7x7x7 M.(2);Aguasx7x7x7 M.(3);Martinez Cuevasx7x7x7 C.(4);Argüelles-Ariasx7x7x7 F.(5);Calvox7x7x7 M.(6);Gargallo-Puyuelox7x7x7 C.J.(7);Zabalzax7x7x7 L.(8);Varela Trastoyx7x7x7 P.(9);Bosca-Wattsx7x7x7 M.M.(10);Ceballosx7x7x7 D.(11);Martinez-Pascualx7x7x7 C.(12);Rodríguez-Morantax7x7x7 F.(13);de Castro Pargax7x7x7 M.L.(14);Suárezx7x7x7 P.(15);Campsx7x7x7 B.(16);Royox7x7x7 V.(17);Bastón-Reyx7x7x7 I.(1);de Francisco x7x7x7 R.(18);Garcia-Lopezx7x7x7 S.(19);Martín-Arranzx7x7x7 M.D.(20);Alonso-Abreux7x7x7 I.(21);Gisbertx7x7x7 J.P.(22);Riverox7x7x7 M.(23);Siciliax7x7x7 B.(24);Nicolásx7x7x7 I.(25);Tellerx7x7x7 M.(26);Ponferradax7x7x7 Á.(27);Ricartx7x7x7 E.(28);Algarax7x7x7 M.(29);Fradejasx7x7x7 P.(30);Robledox7x7x7 P.(31);Maderox7x7x7 L.(32);Elorzax7x7x7 A.(33);Piquerasx7x7x7 M.(34);Zabanax7x7x7 Y.(35);Porto-Silvax7x7x7 S.(1);Domènechx7x7x7 E.(36);Ferreiro-Iglesiasx7x7x7 R.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P060: A2B adenosine receptor deficiency ameliorates chronic murine Crohn’s-like-ileitis.
Year: 2021
Source: ECCO'21 Virtual
Authors: O Connell, L.(1);Olli, K.(2);Wilkinson, C.(3);Collins, C.(1);Jedlicka, P.(4);Aherne, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P060: Alterations of brain structure in Crohn’s disease with extraintestinal manifestations
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Thomann*1, W. Reindl2, P. Thomann3, C. Wolf4, D. Hirjak3, M. Griebe5

Created: Friday, 22 February 2019, 9:49 AM
P060: Post-inflammatory visceral pain induced by DNBS: Preclinical features for novel therapeutics
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Lucarini1*, L. Di Cesare Mannelli1, L. Micheli1, E. Trallori1, L. Antonioli2, M. Fornai2, C. Blandizzi2, C. Ghelardini1

Created: Thursday, 21 February 2019, 9:14 AM
P060: Restoration of occludin and claudin-1 expression in patients with Crohn's disease receiving anti-TNF treatment.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Tsounis, E.(1);Geramoutsou, C.(2);Aggeletopoulou, I.(1,3);Lourida, T.(1);Pastras, P.(1);Theocharis, G.(1);Diamantopoulou, G.(1);Zolota, V.(4);Assimakopoulos, S.F.(5);Bravou, V.(2);Thomopoulos, K.(1);Triantos, C.(6)*;
Created: Friday, 14 July 2023, 10:48 AM
P060: Role of innate lymphoid cells in the chronic colitis under anti-il-17a therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Eun C.S., Han D.S., Park C.H., Lee A.R., Lee Y.R.

Created: Wednesday, 20 February 2019, 10:36 AM
P060: The protective effect of necrosis inhibition on acute murine colitis induced by dextran sulphate sodium
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Kim*1, J. S. Koo1, J. H. Park1, S. H. Hwang1, D. Lee1, J. W. Choe1, J. J. Hyun1, S. W. Jung1, Y. T. Jeen2, S. W. Lee1

Created: Friday, 22 February 2019, 9:41 AM
P060: Unravelling the microbial-derived metabolic alterations in a T-bet-/- x RAG2-/- mouse colitis model
Year: 2022
Source: ECCO'22
Authors: Liu, Z.(1);Lo, J.(1);Alexander, J.(1);Cozzetto, D.(1);Powell, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P061 The molecular landscape of perianal fistula in Crohn’s disease: opportunities for new therapeutic approaches
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Bislenghi1, B. Verstockt2, J. Sabino2, C. Caenepeel3, S. Verstockt3, A. Wolthuis1, M. Ferrante2, A. D’Hoore1, S. Vermeire2, IBD Leuven

Created: Thursday, 30 January 2020, 10:12 AM
P0610: Comparison of endoscopic remission and MRI defined remission using the simplified MaRIA score at week 48 from the PROFILE trial
Year: 2025
Source: ECCO'25
Authors: Bhandarix7x7x7 M.(1)*;Noorx7x7x7 N.(2);Paverdx7x7x7 H.(3);De Paepex7x7x7 K.(4);Godfreyx7x7x7 E.(3);Hickmanx7x7x7 K.(3);Khwajax7x7x7 S.(3);Leex7x7x7 J.(5);Rainex7x7x7 T.(1);Kennedyx7x7x7 N.(6);Upponix7x7x7 S.(3);Parkesx7x7x7 M.(7);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0611: Effectiveness comparisons between tofacitinibx7x7x7 filgotinib and upadacitinib in ulcerative colitis: results from the JAKARTA real-world evidence multicenter study
Year: 2025
Source: ECCO'25
Authors: Buissonx7x7x7 A.(1)*;Tretonx7x7x7 X.(2);Nachuryx7x7x7 M.(3);Uzzanx7x7x7 M.(4);Bouguenx7x7x7 G.(5);Banana Hamadidix7x7x7 A.(1);Amiotx7x7x7 A.(6);Serrerox7x7x7 M.(7);Fumeryx7x7x7 M.(8);Caillox7x7x7 L.(9);Hupéx7x7x7 M.(10);Pereirax7x7x7 B.(1);Altweggx7x7x7 R.(11);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0612: Postoperative outcomes in tofacitinib-treated patients with acute severe ulcerative colitis undergoing total abdominal colectomy
Year: 2025
Source: ECCO'25
Authors: Larsonx7x7x7 C.(1);Berinsteinx7x7x7 J.A.(1x7x7x72);Tedescox7x7x7 N.(1x7x7x72);Seidelinx7x7x7 J.B.(3);Ovesenx7x7x7 P.D.(3);Uzzanx7x7x7 M.(4);Amiotx7x7x7 A.(5);Nuzzox7x7x7 A.(6);Lahariex7x7x7 D.(7);Constantx7x7x7 B.D.(8x7x7x79);Albenbergx7x7x7 L.(9);El-Hussunax7x7x7 A.(10);Bishux7x7x7 S.(1);x7x7x72;Cohen-Mekelburgx7x7x7 S.(1);x7x7x72;Higginsx7x7x7 P.D.R.(1x7x7x72);Steenholdtx7x7x7 C.(11x7x7x712)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0613: Obesity is associated with inferior treatment outcomes in inflammatory bowel disease: a nationwide Dutch registry study
Year: 2025
Source: ECCO'25
Authors: Oomkensx7x7x7 D.(1)*;Mujagicx7x7x7 Z.(2);de Vriesx7x7x7 A.(3);van der Meulen-de Jongx7x7x7 A.(4);Straatmijerx7x7x7 T.(4);Löwenbergx7x7x7 M.(5);van der Marelx7x7x7 S.(6);Westx7x7x7 R.(7);Bodelierx7x7x7 A.(8);van Schaikx7x7x7 F.(9);Visschedijkx7x7x7 M.(10);Duijvesteinx7x7x7 M.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0614: Positive association of inflammatory bowel disease service research activity and adult patient-reported quality of care in the United Kingdom
Year: 2025
Source: ECCO'25
Authors: Mulliganx7x7x7 R.(1)*;Brookesx7x7x7 M.J.(2);Ryanx7x7x7 P.(3);Turnerx7x7x7 J.(4);Beckx7x7x7 L.(1);Selingerx7x7x7 C.P.(5);Hawthornex7x7x7 A.B.(6);Lambx7x7x7 C.A.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0615: Effectiveness and Safety Analysis of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
Year: 2025
Source: ECCO'25
Authors: Wux7x7x7 H.(1);Sux7x7x7 T.(1);Wux7x7x7 L.(1);Zhix7x7x7 M.(1);Yaox7x7x7 J.(1)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0616: ViT-based deep learning and unsupervised clustering analysis in Crohn’s Disease based on body composition to identify distinct phenogroups and predict the effectiveness of anti-TNF therapy
Year: 2025
Source: ECCO'25
Authors: Wangx7x7x7 Y.(1);Dingx7x7x7 Z.(1);Zhangx7x7x7 M.(1);Lix7x7x7 Y.(1)*;
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session
P0617: Feasibility and safety of endoscopic submucosal dissection in inflammatory bowel disease (ESDEUR-IBD): an interim analysis of European retrospective study
Year: 2025
Source: ECCO'25
Authors: Garcíax7x7x7 M.J.(1)*;Frailex7x7x7 M.(1);Katiniosx7x7x7 G.(2);Gubbiottix7x7x7 A.(3x7x7x74);Argyrioux7x7x7 K.(5);González-Partidax7x7x7 I.(6);Gavricx7x7x7 A.(7x7x7x78);de-Castrox7x7x7 M.L.(9);Fousekisx7x7x7 F.(10);Cudero Quintanax7x7x7 L.(11);Suchanekx7x7x7 S.(12x7x7x713);Caronx7x7x7 B.(14);Arranzx7x7x7 L.(15);López-Garcíax7x7x7 A.(16);Ceballosx7x7x7 D.(17);Lolyx7x7x7 J.P.(18);de María Pallaresx7x7x7 P.(19);Bednarskax7x7x7 O.(2);Savarinox7x7x7 E.(3);Skamnelosx7x7x7 A.(10);Schaeferx7x7x7 M.(14);García Romerox7x7x7 D.(15);Rodríguez Pérezx7x7x7 C.(17);Suárez-Ferrerx7x7x7 C.(19);Teránx7x7x7 Á.(1);Riverox7x7x7 M.(1);
Created: Monday, 10 February 2025, 2:00 PM
Guided Poster Session